Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual 2021 | Ven-based salvage followed by ven and DLI maintenance vs. FLAG-ida for R/R AML post-ASCT

Andrius Žučenka • 26 Jul 2021
VJVirtual 2021
Acute Myeloid Leukemia Leukemia Actinomycin Cytarabine Fludarabine G-CSF Idarubicin Venetoclax

Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses venetoclax-based salvage therapy followed by venetoclax and donor lymphocyte infusion (DLI) maintenance vs. fludarabine, cytarabine, G-CSF and idarubicin (FLAG-ida) for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (ASCT).

More from Andrius Žučenka

The effectiveness of sequential alloSCT in patients with venetoclax-exposed R/R AML or MDS-IB2 3:29
The effectiveness of sequential alloSCT in patients with venetoclax-exposed R/R AML or MDS-IB2
Andrius Žučenka • 15 Jun 2025
ADVANCED: a novel conditioning regimen for alloSCT in patients with adverse-risk AML 3:21
ADVANCED: a novel conditioning regimen for alloSCT in patients with adverse-risk AML
Andrius Žučenka • 15 Jun 2025
Efficacy and safety of combining venetoclax with cytarabine and actinomycin D in R/R AML 3:13
Efficacy and safety of combining venetoclax with cytarabine and actinomycin D in R/R AML
Andrius Žučenka • 15 Jun 2025
The evolving treatment paradigm for unfit patients with AML 4:50
The evolving treatment paradigm for unfit patients with AML
Andrius Žučenka • 7 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals